JP2002542281A5 - - Google Patents

Download PDF

Info

Publication number
JP2002542281A5
JP2002542281A5 JP2000613414A JP2000613414A JP2002542281A5 JP 2002542281 A5 JP2002542281 A5 JP 2002542281A5 JP 2000613414 A JP2000613414 A JP 2000613414A JP 2000613414 A JP2000613414 A JP 2000613414A JP 2002542281 A5 JP2002542281 A5 JP 2002542281A5
Authority
JP
Japan
Prior art keywords
disorder
prevention
treatment
pharmaceutical composition
depression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000613414A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002542281A (ja
Filing date
Publication date
Priority claimed from FR9905338A external-priority patent/FR2792835B3/fr
Application filed filed Critical
Publication of JP2002542281A publication Critical patent/JP2002542281A/ja
Publication of JP2002542281A5 publication Critical patent/JP2002542281A5/ja
Pending legal-status Critical Current

Links

JP2000613414A 1999-04-27 2000-04-25 あらゆる気分障害、適応障害または不安−抑うつ混合障害の治療または予防に有用な医薬の調製のためのサレドゥタントおよび医薬として許容されるその塩類の使用 Pending JP2002542281A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9905338A FR2792835B3 (fr) 1999-04-27 1999-04-27 Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression
FR99/05338 1999-04-27
PCT/FR2000/001084 WO2000064423A2 (fr) 1999-04-27 2000-04-25 Utilisation du saredutant et de ses sels pharmaceutiquement acceptables dans le traitement ou la prevention des troubles de l'humeur d'adaptation et de l'anxiete-depression

Publications (2)

Publication Number Publication Date
JP2002542281A JP2002542281A (ja) 2002-12-10
JP2002542281A5 true JP2002542281A5 (enExample) 2006-01-19

Family

ID=9544931

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000613414A Pending JP2002542281A (ja) 1999-04-27 2000-04-25 あらゆる気分障害、適応障害または不安−抑うつ混合障害の治療または予防に有用な医薬の調製のためのサレドゥタントおよび医薬として許容されるその塩類の使用

Country Status (32)

Country Link
US (3) US6573281B1 (enExample)
EP (1) EP1173179B1 (enExample)
JP (1) JP2002542281A (enExample)
KR (1) KR20020001850A (enExample)
CN (1) CN1172669C (enExample)
AR (1) AR023597A1 (enExample)
AT (1) ATE234617T1 (enExample)
AU (1) AU764304B2 (enExample)
BG (1) BG65472B1 (enExample)
BR (1) BR0010006A (enExample)
CA (1) CA2370834C (enExample)
CZ (1) CZ294904B6 (enExample)
DE (1) DE60001725T2 (enExample)
DK (1) DK1173179T3 (enExample)
EE (1) EE05211B1 (enExample)
ES (1) ES2193065T3 (enExample)
FR (1) FR2792835B3 (enExample)
HU (1) HUP0200969A3 (enExample)
IL (1) IL145269A0 (enExample)
MX (1) MXPA01010904A (enExample)
NO (1) NO20015228L (enExample)
NZ (1) NZ513851A (enExample)
PL (1) PL196479B1 (enExample)
PT (1) PT1173179E (enExample)
RU (1) RU2238726C2 (enExample)
SI (1) SI1173179T1 (enExample)
SK (1) SK285459B6 (enExample)
TR (1) TR200102512T2 (enExample)
TW (1) TWI225399B (enExample)
UA (1) UA69441C2 (enExample)
WO (1) WO2000064423A2 (enExample)
ZA (1) ZA200107143B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2792835B3 (fr) * 1999-04-27 2001-05-25 Sanofi Sa Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression
WO2001077069A1 (en) * 2000-04-06 2001-10-18 Astrazeneca Ab Naphthamide neurokinin antagonists for use as medicaments
ATE400563T1 (de) * 2000-04-06 2008-07-15 Astrazeneca Ab Neue neurokinin-antagonisten zum gebrauch als arzneimittel
US6846814B2 (en) 2000-04-06 2005-01-25 Astra Zeneca Ab Neurokinin antagonists for use as medicaments
US6903092B2 (en) 2000-04-06 2005-06-07 Peter Bernstein Naphthamide neurokinin antagonists for use as medicaments
GB0019008D0 (en) * 2000-08-04 2000-09-27 Astrazeneca Ab Therapeutic compounds
SE0003476D0 (sv) 2000-09-28 2000-09-28 Astrazeneca Ab Compounds
FR2904221B1 (fr) * 2006-07-31 2008-09-12 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et la fluoxetine.
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
FR2912058A1 (fr) * 2007-02-07 2008-08-08 Sanofi Aventis Sa Utilisation d'un compose antagoniste des recepteurs nk2 de la neurokinine a pour la preparation de medicaments utiles pour la prevention et le traitement des dysfonctions sexuelles
ES2382415T3 (es) * 2007-09-14 2012-06-08 F. Hoffmann-La Roche Ag Derivados de piperidina como antagonistas de receptores de NK3
US20090076083A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched saredutant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99320A (en) * 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical compositions containing them
FR2695626B1 (fr) * 1992-09-17 1994-12-02 Lebroch Yannick Dispositif de gobelet adaptable sur un conteneur de boisson.
FR2696178B1 (fr) * 1992-09-30 1994-12-30 Sanofi Elf Amides basiques quaternaires, procédé pour leur préparation et compositions pharmaceutiques en contenant.
FR2700472B1 (fr) * 1993-01-19 1995-02-17 Rhone Poulenc Rorer Sa Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
US5512680A (en) * 1993-02-26 1996-04-30 Sanofi Process for the preparation of an optically pure aminoalcohol
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
US5554644A (en) * 1994-06-08 1996-09-10 Warner-Lambert Company Tachykinin (NK2) antagonists
FR2792835B3 (fr) * 1999-04-27 2001-05-25 Sanofi Sa Utilisation du saredutant pour la preparation de medicaments utiles dans le traitement ou la prevention de l'ensemble des troubles de l'humeur, des troubles de l'adaptation ou des troubles mixtes anxiete-depression

Similar Documents

Publication Publication Date Title
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
WO2004066910A8 (en) Controlled release modifying complex and pharmaceutical compositions thereof
WO2003015779A3 (de) Matrixkontrolliertes transdermales therapeutisches system zur anwendung von pramipexol und ropinirol
JP2002542281A5 (enExample)
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
EP1232757A4 (en) MEDICINE FOR DISEASES ASSOCIATED WITH LOSS OF BONE SUBSTANCE
SI1546127T1 (sl) Novi pirimidinamidni derivati in njihova uporaba
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
NO20013060D0 (no) Kontrollert frigjörende farmasöytisk preparat med tilidinmesylat som virkestoff
ATE262893T1 (de) Darreichungsformen zur behandlung von oralen mykosen
EA201101119A1 (ru) Дозируемая форма, содержащая пантопразол в качестве активного ингредиента
CA2370834A1 (en) Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders
MXPA03000439A (es) Nueva forma de (r)-n-(5-metil -8-(4-metilpiperazin -1-il) -1,2,3,4-tetrahidro-2-naftil) -4-morfolinobenzamida.
NO20031410L (no) Anvendelse av distamycinderivater for fremstilling av medikamenter
WO2004098577A3 (en) Dosage form containing (s)-pantoprazole as active ingredient
WO2004037199A3 (en) Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
CA2727722A1 (en) Use of dihydroimidazolones for the treatment of anxiety in dogs
HRP20020989B1 (hr) Enantiomer 1,2-aneliranog kinolina koji inhibira farnezil transferazu
PT1406859E (pt) Derivados substituídos de 4-aminociclo-hexanol
SE0000303D0 (sv) Novel compounds
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
EP1741430A4 (en) MEANS FOR THE TREATMENT OF PSYCHONEUROTIC DISEASES
AU2002220654A1 (en) Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
MXPA05009921A (es) Agentes terapeuticos y/o preventivos para enfermedades cutaneas cronicas.
DE60235965D1 (de) Kombination aus levosimendan und einer kalziumquelle zur behandlung von herzinsuffizienz